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Abstract
Background: The L-type amino acid transporter 1 (LAT1/SLC7A5) transports essential amino acids across the plasma
membrane. While LAT1 is overexpressed in a variety of human neoplasms, its expression and its role in thyroid
cancer is currently unknown. Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy for which no
effective therapy exists. The purpose of this study was to explore whether the inhibition of LAT1 in ATC would
affect tumor growth both in vitro and in vivo.
Methods: LAT1 was pharmacologically blocked by JPH203 in human ATC and papillary thyroid cancer (PTC) cell
lines. The effects on proliferation and mTORC1 activity were addressed in vitro. A genetically engineered mouse
model of ATC was used to address the effect of blocking LAT1 on tumor growth in vivo. SLC7A5 transcription was
measured in patient-derived ATC samples to address the clinical relevance of the findings.
Results: LAT1 block by JPH203 reduced proliferation and mTORC1 signaling in human thyroid cancer cell lines.
SLC7A5 transcription was upregulated in ATC tissues derived from a genetically engineered mouse model and in
ATC samples recovered from patients. JPH203 treatment induced thyroid tumor growth arrest in vivo in a fully
immunocompetent mouse model of thyroid cancer. Additionally, analysis of publicly available datasets of thyroid
carcinomas revealed that high LAT1 expression is associated with potentially untreatable PTC presenting reduced
NIS/SLC5A5 transcription and with ATC.
Conclusions: These preclinical results show that LAT1 inhibition is a novel therapeutic approach in the context of
thyroid cancers, and more interestingly in untreatable thyroid cancers.
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Background
A major hallmark of cancer is sustained proliferative sig-
naling [1], which allows cells to divide rapidly in an un-
controlled way. Proliferation is highly energy demanding
and depends on the availability of nutrients in the tumor
microenvironment. Among these nutrients, essential
amino acids (EAA) require an active transport across the
plasma membrane in order to be available for protein
synthesis. The L-type amino acid transporter 1 (LAT1/
SLC7A5) is a membrane transporter for EAA such as
leucine and phenylalanine. LAT1 functions in a Na+-in-
dependent manner [2] and exchanges glutamine for sub-
strate EAA [3]. LAT1 is covalently attached to 4F2hc
(also termed CD98 or SLC3A2), which is required for its
trafficking to the membrane [4]. LAT1 is expressed in
the brain endothelium, placenta and spleen [2, 5, 6].
Interestingly, LAT1 has been shown to be overexpressed
during the development of a variety of different tumors
such as prostate, breast, gastric, lung and pancreatic can-
cers [7–11]. It works in concert with ASCT2/SLC1A5
that effects inwards transport of glutamine and thus par-
ticipates in establishing the glutamine gradient that is re-
quired for LAT1-dependent leucine uptake [3]. Likewise,
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ASCT2/SLC1A5 is also elevated in numerous cancers
[12–14].
Thyroid cancer is the most frequent endocrine neopla-
sia and its incidence has dramatically increased during
the past 30 years [15]. In 2016, thyroid cancer ranks fifth
in the number of all estimated new cases of cancer in fe-
males in the US [16]. Papillary thyroid carcinoma (PTC)
is the most frequent type, representing about 80% of all
cases [17]. PTC is well managed in the clinic by thyroid-
ectomy alone or complemented with radioactive iodine
treatment with a 5-years survival rate of 94% [18]. In
contrast, patients that are diagnosed with anaplastic thy-
roid carcinoma (ATC), one of the most aggressive tu-
mors known in humans, have a dismal prognosis with a
median survival rate of 5 months and a 20% 1-year sur-
vival [19]. Although ATC represents only about 2% of
thyroid carcinoma [17], its invariable fatal outcome un-
derscores that new therapeutic strategies are urgently
needed to combat this highly aggressive disease.
BRAF is part of the RAS-RAF-MEK-ERK pathway,
and is mutated in human cancers with a frequency of 8%
[20]. More than 90% of BRAF mutations are caused by a
T1799A transversion, resulting in BRAFV600E mutant
protein expression. In thyroid cancer, this mutation is
found in 40% of the cases overall and 25% of ATC cases
[21]. A conditional mouse model mimicking BRAFV600E
is able to initiate tumor formation in lung [22], melano-
cytes [23] and pancreas [24]. Regarding thyroid cancer,
thyroid-specific BRAFV600E expression leads to PTC in
mice, thus confirming the importance of the mutation in
this pathology [25]. Phosphoinositol 3 kinase (Pi3’K)
mutations are frequent (23%) in ATC [26]. When the ac-
tivated mutant PIK3CAH1047R is expressed in mice thy-
roids concomitantly with BRAFV600E, the progression
from PTC to ATC resulting in mice death can occur
within 3 to 6 months [27]. This model closely mimics
the human ATC.
Despite previous associations between LAT1 and other
cancer types, the role of LAT1 in thyroid cancer has not
yet been studied. Here, we assessed whether LAT1 is up-
regulated during the progression of thyroid cancer and
whether the inhibition of LAT1 by a potent and selective
LAT1 inhibitor would reduce thyroid cancer growth
both in vitro and in vivo. Our data show that LAT1 is
highly expressed in human thyroid cancer cell lines and
that LAT1 inhibition by JPH203 reduces proliferation
and impairs mTORC1 activity. In vivo, JPH203 exerted a
stalemate of tumor burden increase in a mouse model of
thyroid cancer. In line with these findings, SLC7A5 tran-
scription was elevated in human PTC samples and even
further increased in ATC samples compared to normal
thyroid tissues. In PTC, SLC7A5 level was found associ-
ated with worse prognosis and reduced SLC5A5 (Sodium
iodine symporter) transcription. This is the first study
showing a critical role for LAT1 in a solid tumor in a
genetically engineered mouse model baring fully compe-
tent immune system. LAT1 inhibition in highly aggres-
sive thyroid cancers might be a novel therapeutic
strategy to stop tumor growth in thyroid cancer patients.
Methods
JPH203
JPH203 was synthesized following the route described in
ref. [28]. The analytical data for all intermediates and
JPH203 (1H-NNMR, 13C-NMR, 18F-NMR, where applic-
able) were in agreement with the expected structures.
The analytical data for JPH203 are included in the SI.
Animals
All animal experiments were in accordance with the
Swiss animal welfare law and were approved by the local
veterinary authority in Bern (license number: BE92/15).
BrafCA, Pik3caLat and Thyro::CreERT2 mice were de-
scribed previously [22, 25, 27, 29]. Thyrocyte-specific
CreERT2 activation was achieved by intraperitoneal injec-
tion of 1 mg of tamoxifen dissolved in 100 μl of peanut
oil into 5–7 weeks old mice for five consecutive days.
MEK/PI3K inhibition in mice
Double mutant BRAFV600E PIK3CAH1047R mice, two
months after tamoxifen injections were treated by oral
gavage with 5 mg/kg of PD-325901 or 50 mg/kg of
GDC-0941, formulated in Hydroxypropyl methylcellulose
0.5%, Tween-80 0.2% for 10 consecutive days. Vehicle only
was used as a control. Tumours were resected 4 h after
the last gavage and snap frozen prior to RNA extraction.
Small drug inhibitors were purchased from Abmole.
Cell lines
8505c cells were purchased from ECACC (cat. no.
94090184), LNCaP cells were purchased from
Sigma-Aldrich (cat. no. 89110211), SW1736 cells were
purchased from CLS (cat. no. 300453). Hth104, KTC1
and TPC-1 cells were a gift from Prof. James Fagin
(MSKCC, New York, USA) and were cultured in RPMI
medium (Sigma-Aldrich, cat. no. R8758). K1 cells were a
gift from Prof. James Fagin (MSKCC, New York, USA)
and cultured in DMEM:F12 medium (Gibco, cat. no.
11320–074). HT-29 cells were purchased from ATCC
(cat. no. HTB-38) and cultured in Modified McCoy’s 5A
medium (Gibco, cat. no. 26600–080). Media of all cell
lines were supplemented with 10% FBS (Gibco, cat.
no.10270), 100 U/ml penicillin (Sigma-Aldrich, cat. no.
P0781), 0.1 mg/ml streptomycin (Sigma-Aldrich, cat. no.
P0781). Media of 8505c, LNCaP and K1 cells were add-
itionally supplemented with 1X Non-Essential Amino
Acids (NEAA) (BioConcept, cat. no. 5-13 K00). All cell
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lines were kept up to 50 passages or 6 months, which-
ever limit was reached first.
Patients
The use of PTC and ATC patient histological tissue sec-
tions obtained at the University Hospital of Bern (Insel-
spital) was approved by the Cantonal Ethics Committee
Bern (ref. no. 200/2014). Histological diagnosis was per-
formed by one of the authors (M.S. D.).
Real-time PCR
Total RNA from cells and mouse thyroid tissue was ex-
tracted by using Qiazol reagent (Qiagen, cat. no. 79306)
according to the manufacturer’s protocol. Total RNA
from formalin-fixed paraffin-embedded human thyroid
cancer tissue was extracted using a High Pure FFPET
RNA isolation kit (Roche, cat. no. 06868517001) accord-
ing to the manufacturer’s protocol. Reverse-transcription
was performed with Superscript II (Invitrogen, cat. no.
18064–014) following the manufacturer’s protocol. Taq-
Man real-time primer/probe sets were purchased from
Applied Biosystems: Slc7a5 Mm00441516_m1, SLC7A5
Hs00185826_m1, Slc3a2 Mm00500521_m1, Slc1a5 Mm
00436603_m1, Slc38a2 Mm00549967_m1, Atf5 Mm0417
9654_m1, actb 4352341E, Tuba1a Mm00846967_g1,
ACTB 4326315E. Quantifications were performed using
a ViiA 7 real-time PCR machine (Applied Biosystems).
Relative differences in gene expression levels were
assessed by normalizing the Ct value of the target gene
to the Ct value of the housekeeping gene and quantified
by the 2-ΔΔCt method.
Western blotting
Proteins were extracted in RIPA buffer (20 mM
Tris-base pH 8, 150 mM NaCl, 1% Triton X-100, 0.1%
SDS, 0.5% sodium deoxycholate) supplemented with
Halt protease/phosphatase inhibitor cocktail (Pierce, cat.
no. 78444). Protein concentration was assessed by Pierce
BCA protein assay kit (Thermo Scientific, cat. no.
23225) and 10–30 μg total protein were separated by
SDS-PAGE. Protein gels were transferred onto nitrocel-
lulose membranes and blocked in 5% BSA in TBS. Pri-
mary antibody used (purchased from Cell signaling
unless specified): P-p70S6K (cat. no. 2708), p70S6K (cat.
no. 2708) P-S6 S240/244 (cat. no. 5364), P-S6 S235/236
(cat. no. 4858), S6 (cat. no. 2217), P-ERK (cat. no. 9107),
Tot-ERK (cat. no. 4370), P-AKT S473 (cat. no. 4060),
pan-AKT (cat. no. 2920), β-actin (Sigma-Aldrich, cat.
no. A5316) and LAT1 (TransGenic Inc., cat. no.
KE026). Primary antibodies were detected by using
goat anti-rabbit IR680 (Li-Cor Bioscience, cat. no.
926–68071) and goat anti-mouse IR800 (Li-Cor Bio-
science, cat. no. 926–32210) and imaged by a LI-COR
OdysseySA imaging system.
Proliferation assays
Cells were seeded at 10% confluency in a 96-well plate.
They were allowed to adhere overnight, washed once
with PBS and incubated in custom media: Earle’s bal-
anced salt solution (EBSS) plus 5.5 mM D-glucose,
0.025 mM phenol red (Gibco, cat. no. 24010–043), 10%
FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin,
2 mM L-glutamine, 1X NEAA (BioConcept, cat. no.
5-13 K00) and 1X MEM vitamin solution (Gibco, cat.
no. 11120–052). For proliferation assays at different
concentrations of essential amino acids (EAA),
medium described above was supplemented with 1X
MEM amino acids solution (Gibco, cat. no. 11130–
051; see Additional file 1: Table S1 for detailed com-
position) and a two-fold serial dilution with the
EAA-free medium was performed. Dose-response
curves were carried out in custom medium with
0.125X MEM amino acids solution (Table S1). LNCaP
wells were coated overnight with 0.1 mg/ml
poly-D-lysine (Sigma-Aldrich, cat. no. P6407-5MG) in
order to avoid detachment during washings. Cells
were treated with the indicated concentration of
JPH203 for two population doubling times (48 h for
8505c, SW1736 and K1; 96 h for LNCaP) and fixed
with 10% buffered formalin, stained with 0.2% crystal
violet (Sigma-Aldrich, cat. no. C3886-25G) in 2%
ethanol, washed 5 times in dH2O and lysed with
100 μL 1% SDS. OD at 550 nm was measured with a
microplate reader and normalized to DMSO control.
Ultrasound imaging and JPH203 treatment in vivo
Tumor burden was measured by quantifying the area of
the largest thyroid cross-section observed (mm2) and
normalized to the size at the beginning of the experi-
ment as described previously [30]. JPH203 was diluted
in 40% (w/v) Captisol® (CyDex Pharmaceuticals) at a
concentration of 7.5 mg/ml and sonicated for 1 min.
Mice were treated for 5 consecutive days/week for
45 days with 200 μl of 7.5 mg/ml JPH203 or vehicle by
i.p. injection, corresponding to a dose of 50 mg/kg/day.
Immunofluorescence staining and TUNEL
Tissue section and Tunel stains were performed as de-
scribed before [30]. Primary antibodies anti-Ki67
(Abcam cat. no. ab16667,) and anti-BrdU (Abcam cat.
no. ab6326,) were incubated overnight at 4 °C. Sec-
ondary antibodies goat anti-rabbit Alexa-488 (Invitro-
gen, cat. no. A11034,) and goat anti-rat Alexa-555
(Invitrogen, cat. no. A21434,) were used to detect
antigen-antibody complexes; slides were counter
-stained with DAPI (500 ng/ml, Sigma Aldrich, cat.
no. 32670-25MG).
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Slides scanning
Slides were scanned using a Pannoramic Midi digital
slide scanner (3DHISTECH Ltd.) and analyzed by Cell-
Quant software (3DHISTECH Ltd.). To quantify Ki67/
BrdU positive cells, an average of 8 nonconsecutive sec-
tions of the tumor were used for each sample, 4 sections
for TUNEL.
3H-leucine uptake assay
Cells were seeded at 60% confluency in a 96-well plate
using complete culture medium and cultured until con-
fluent. Cells were washed three times with 37 °C
pre-warmed Na+-free Hank’s balanced salt solution
(HBBS) containing 125 mM choline-Cl, 25 mM HEPES,
4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 1.3 mM
CaCl2 and 5.6 mM glucose (pH 7.4) and further incu-
bated in the same buffer at 37 °C for 7 min. L-leucine
uptake was measured for 3 min at 37 °C in the same
buffer containing 30 μM L-[3H]leucine (60 Ci/mmol)
and different concentrations of JPH203. Uptake was ter-
minated by removing the solution followed by three
washings with ice-cold Na+-free HBBS. Cells were lysed
and mixed with Microscint20 (Perkin-Elmer Life Sci-
ences). The radioactivity was measured with a scintilla-
tion counter (TopCount NXT, Perkin-Elmer Life
Sciences).
3H-leucine efflux assay
The same protocol as for the uptake was used with the
following differences after the initial washing- and
starvation-step. Cells were preloaded for 5 min at 37 °C
in the Na+-free HBBS containing 30 μM L-[3H]leucine
(60 Ci/mmol). After washing three times with Na+-free
HBBS (4 °C), efflux of radioactivity was induced by incu-
bation in the presence or absence of indicated concen-
trations of test compounds for 1.5 min at 37 °C. The
medium was then collected and its radioactivity was
counted. The cells were washed three times with
ice-cold Na+-free HBBS. Cells were lysed and mixed
with Microscint20 (Perkin-Elmer Life Sciences). The
radioactivity was measured with a scintillation counter
(TopCount NXT, Perkin-Elmer Life Sciences). The
L-[3H]leucine efflux values were expressed as percentage
radioactivity (radioactivity of medium)/(radioactivity of
the medium + radioactivity of the cells)).
Statistical analysis
Data are expressed as average ± SD. Statistical analyses
were conducted using GraphPad Prism 7 (GraphPad Soft-
ware). IC50 and IG50 values were calculated by nonlinear
regression. Proliferation assays at different amino acid
concentrations were analyzed by multiple t-test with
Holm-Sidak correction. Transcript levels of amino acid
transporters in thyroid tumors were analyzed with a
Kruskal-Wallis test with Dunn’s correction. Drug-induced
Slc7a5 reduction was analysed by an ordinary one-way
ANOVA test. Tumor growth in vivo was analyzed with a
two-way ANOVA test with Bonferroni correction. Prolif-
eration and apoptosis markers of tumors were compared
with a two-tailed Mann-Whitney test. Patient survival was
analyzed with a log-rank test. Gene co-occurrence analysis
was analyzed with a one-sided Fisher’s exact test. P ≤ 0.05
was considered as statistically significant; * = p < 0.05, ** =
p < 0.01, *** = p < 0.001.
Results
Expression and functional characterization of LAT1 in
thyroid cancer cell lines
SLC7A5 transcripts were found in all 6 thyroid cancer
cell lines tested (Fig. 1a) with variable levels. In the
HT-29 colon carcinoma cell line, SLC7A5 transcription
was 8-fold higher compared to K1 (used as basal level =
1), whereas in the prostate cancer cell line LNCaP,
SLC7A5 transcripts were undetectable (Fig. 1a).
We next evaluated LAT1 expression by western blot-
ting. The specificity of the antibody employed was con-
firmed by the absence of signal in LNCaP cells and a
strong signal in HT-29 cells (Fig. 1b). LAT1 expression
was found in all cell lines with TPC-1 expression the
highest level and K1 the lowest.
To explore the effects of blocking leucine transport
through LAT1 in thyroid cancer cell lines we synthesized
the highly specific LAT1 inhibitor JPH203 [31]. 3H-leu-
cine uptake was measured for 8505c, SW1736 and
HT-29 cells in the presence of different concentrations
of JPH203 (Fig. 1c). HT-29 cells served as positive con-
trol. The IC50 values for each cell line are summarized
in Fig. 1d. 3H-leucine uptake was not affected by JPH203
in LNCaP (Additional file 1: Figure. S1), in agreement
with the lack of LAT1 expression in these cells. To bet-
ter understand the mechanism of action of JPH203 we
compared its effect on 3H-leucine efflux to L-tyrosine
and L-leucine, which are both substrates [32]. As shown
in Fig. 1e, JPH203 behaves as a non-substrate and pos-
sibly competitive inhibitor of LAT1, which prevents the
efflux of 3H-leucine induced by leucine and tyrosine.
JPH203 effect on cell proliferation is dependent on EAA
concentration and LAT1 expression
The concentration of most EAAs in conventional
media (Table S1) greatly exceeds the level found in
plasma (supplementary data of [33]). In order to
mimic physiological leucine concentration we pre-
pared a customized culture medium that contained
various concentrations of EAA in fractions of the
standard cell culture levels (1X EAA). JPH203 at
10 μM did not reduce cell proliferation at 1X EAA
(Fig. 2) in any cell lines. However, when EAA
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concentrations were reaching plasma level (between
0.25/0.125X EAA), the proliferation of 8505c (Fig. 2a) and
SW1736 cells (Fig. 2b) was significantly reduced by
JPH203, while neither K1 nor LNCaP proliferation was
significantly affected even at low concentrations of EAA
(Fig. 2c and d ) by this 10 μM dose of JPH203.
Dose-response inhibition curves of JPH203 were then per-
formed in medium supplemented with 0.125X EAA. K1
Fig. 1 LAT1 is highly expressed in ATC cell lines and JPH203 inhibits leucine uptake. a SLC7A5 transcription levels were quantified by Real-time
PCR in three PTC cell lines (K1, KTC1, TPC-1) and three ATC cell lines (8505c, SW1736, Hth104). HT-29 cells served as positive control and LNCaP
cells as negative control. LAT1 transcription levels were normalized to β-actin and plotted as fold change relative to K1 transcription level. b: LAT1
protein expression was quantified by western blotting in the cell lines described in (a). HT-29 cells served as positive control and LNCaP cells as
negative control to confirm antibody specificity. Integrated signal of the LAT1 band was normalized to β-actin and displayed as fold change
relative to K1. c 3H-Leucine uptake assay was performed in 8505c, SW1736, and HT-29. Dose-response curve was conducted in triplicate and
3H-Leucine uptake at each concentration was normalized to the uptake at the lowest JPH203 concentration (1 nM). These results represent the
average of three independent experiments. d IC50 values for each cell line were calculated from (c). (e): Efflux of preloaded L-[
3H]leucine induced
by the two substrates leucine and tyrosine, and the inhibitor JPH203. The efflux of preloaded L-[3H]leucine was measured for 1.5 min in the
presence or absence (control) of extracellularly applied substrates (100 μM leucine or tyrosine) and/or inhibitor (5 μM or 100 μM JPH203). The
radioactivity released from the cells was expressed as percent of the total preloaded radioactivity (% radioactivity). Leucine efflux of the control
(30–40% radioactivity over all experiments) was set as 0% radioactivity and the samples were normalized to the control
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Fig. 2 (See legend on next page.)
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cells were the least sensitive with a relative IG50 of
16.9 μM (Fig. 2e) while the three ATC cell lines and the
PTC cell line TPC1 presented higher sensitivity to the
drug with relative IG50 ranging between 1.3 and
4.4 μM. Furthermore, in LAT1-negative LNCaP cells
the relative IG50 was extrapolated from the curve to
be over 100 μM (Fig. 2e).
LAT1 inhibition affects mTORC1 signaling
Since LAT1 participates in mTORC1 activity [3] we
measured Phospho-p70S6K and Phospho-S6 levels as a
readout of mTORC1 in JPH203-treated cells. Both levels
were significantly decreased in all thyroid cancer cell
lines tested by 10 μM JPH203 when cultured in 0.125X
EAA medium (Fig. 3a and b). In LNCaP cells, JPH203
(See figure on previous page.)
Fig. 2 JPH203 reduces proliferation of the ATC cell lines 8505c and SW1736 when EAA concentrations in medium were lowered to plasma level.
Proliferation assays of two ATC cell lines (a) 8505c and (b) SW1736, the PTC cell line (c) K1 and (d) LNCaP cells as negative control were
performed at different EAA concentrations (1X - 0.125X, see Table S1 for detailed composition). Cells were plated in sixplicate using normal
growth medium, after overnight incubation cells were washed with PBS and medium containing specific EAA concentration was added. Cells
were treated (DMSO/10 μM JPH203) and fixed after (a-c) 48 h or (d) 96 h (two population doubling times). Each condition was normalized to the
proliferation of DMSO-treated 1X EAA. These results represent the average of three independent experiments. Statistical analysis was performed
by using multiple t-tests, one per row, and Holm-Sidak correction for multiple comparisons. e Dose-response curves for JPH203 were conducted
with three PTC cell lines (K1, KTC1, TPC-1) and three ATC cell lines (8505c, SW1736, Hth104) and LNCaP cells as a negative control using medium
containing 0.125X EAA (see Table S1 for detailed composition). Cells were plated in triplicate using normal growth medium, after overnight
incubation cells were washed with PBS and 0.125X EAA was added. Cells were treated with different concentrations of JPH203 between 2.5 nM
and 50 μM or DMSO as control. 8505c, SW1736, Hth104, KTC1, TPC-1 and K1 cells were incubated for 48 h; LNCaP cells for 96 h (two population
doubling times) and growth was normalized to DMSO. These results represent the average of three independent experiments.
Fig. 3 JPH203 decreases mTORC1 activity, but not ERK or AKT Western blot analyses of mTORC1, ERK and AKT activity in thyroid cancer cell lines
after JPH203 treatment. P-p70 S6 kinase, p-ERK and p-AKT levels were assayed in (a) PTC cell lines and (b) ATC cell lines and (c) LNCaP as
negative control. Cells were plated in triplicates using normal growth medium, after overnight incubation cells were washed and 0.125X EAA was
added. Cells were treated with 10 μM JPH203 or DMSO as control and lysed after 24 h
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did not alter p-S6 levels consistently under these condi-
tions (Fig. 3c). The ERK pathway was not altered by this
treatment in any cells. AKT phosphorylation was not re-
duced and sometimes further elevated (SW1736 in Fig 3).
Blocking LAT1 exerts a strong cytostatic effect on thyroid
cancer growth in vivo
Next, we investigated whether LAT1 was upregulated
during the development of thyroid cancer in our mouse
model [27]. Interestingly, Slc7a5 and Slc3a2 transcript
levels were both significantly increased in BRAFV600E/PIK3-
CAH1047R double-mutant tumors (4.8-fold and 2.3-fold, re-
spectively) compared to wild-type samples. In BRAFV600E
single-mutant samples there was a tendency of increased
Slc7a5 and Slc3a2 transcript levels, however this was not
statistically significant (Fig. 4a). Slc1a5 encoding ASCT2,
which fuels the glutamine gradient necessary for LAT1 ac-
tivity, was not found elevated in both single- and
double-mutant tumors. Interestingly, the surrogate trans-
porter SNAT2 encoded by Slc38a2, which is a sodium
-dependent glutamine transporter, was 2.2-fold upregulated
in BRAFV600E/PIK3CAH1047R double-mutant tumors,
which was close to being statistically significant
(p = 0.0571, Fig. 4a). The mouse model was therefore
shown to be suitable to explore if blocking LAT1 would
affect thyroid cancer growth in vivo.
Slc7a5 transcription has been shown to be driven by
c-MYC [34]. We therefore tested if it was indeed the
case in our model. BRAFV600E/PIK3CAH1047R double
-mutant Mice, two months after tumor induction, were
treated with either a MEK inhibitor (PD-325901) and a
class I Pi3’K inhibitor (GDC-0941) for ten days prior to
dissection and LAT1 transcription analysis (Fig. 4b).
While Pi3’K inhibition did not induced any change in
Slc7a5 transcript abundance, MEK inhibition induced
more than 50% reduction.
Thyroid tumorigenesis was induced in 6-weeks old
adult BrafCA/+;Pik3caLat/+;Thyro::CreERT2 mice by tam-
oxifen injection, which results in thyrocyte-specific ex-
pression of BRAFV600E and PIK3CAH1047R. A cohort of
12 mice was separated into two groups that were treated
with either vehicle or 50 mg/kg JPH203 i.p. daily for five
days per week during 6.5 weeks (Fig. 5a). Weekly ultra-
sound imaging revealed that JPH203 exerted an arrest of
tumor growth already after 14 days of treatment,
whereas tumors of vehicle-treated mice continued to
grow until the end of the experiment (Fig. 5c). Represen-
tative images comparing the tumor burden at day 45
(end of the study) to day 0 (start of treatment) illustrate
the significant difference between vehicle- and JPH203
-treated mice (Fig. 5b). In this model of thyroid cancer,
all thyrocytes are undergoing recombination and
Fig. 4 The inhibition of LAT1 by JPH203 induces a cytostatic growth arrest in an ATC mouse model in vivo. a Slc7a5, Slc3a2, Slc1a5 and Slc38a2
transcription levels were quantified in BRAFV600E single-mutant (n = 5) and BRAFV600E/PIK3CAH1047R double-mutant (n = 11) mouse thyroid tumors
4 months after induction and compared to wild-type thyroids (n = 7) level. Transcription levels of each gene were normalized to Tuba1a and
plotted as fold change relative to wild-type level. Statistical analysis was performed using a Kruskal-Wallis test with Dunn’s correction for multiple
comparisons. b Outline of experimental procedure, as described in the text. c Slc7a5, transcription level was quantified in BRAFV600E/PIK3CAH1047R
double-mutant mouse thyroid tumors after 10 days of treatments with PD-325901 at 5 mg/kg (n = 4) or GDC-0941 at 50 mg/kg (n = 5) or
vehicle (n = 3)
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transformation, inducing a cancerization of the whole
thyroid. Therefore the assessment of whole thyroid size
for tumor burden was used. Three mice (2 in the vehicle
group, 1 in the JPH203 group) were excluded from the
evaluation of the experiment, because they reached thy-
roid cancer-related end-point criteria (sudden > 15%
bodyweight loss) before the end of the study. There was
otherwise no difference in body weight between vehicle-
and JPH203-treated mice (Fig. 5d). This suggests that
JPH203 treatment has no striking adverse effects at the
dosage employed (50 mg/kg i.p.).
LAT1 inhibition increased TUNEL-positive nuclei and
activated the amino acid stress response in thyroid
tumors in vivo
Hematoxylin/Eosin stains of thyroid sections revealed
that 1 out 4 controls presented signs of progression from
PTC to ATC (Fig. 6a) while none of the JPH203 treated
animals presented ATC progression (Fig. 6b). We then
analyzed tissue sections by immunofluorescence staining
to quantify proliferation markers (Ki67, BrdU) and
apoptosis marker TUNEL. The number of both Ki67-
(Fig. 6c) and BrdU-positive cells (Fig. 6d) were reduced
in JPH203-treated mice (15% and 17%, respectively),
however, this decrease was not statistically significant.
On the other hand, we found a statistically significant
elevation of TUNEL-positive bodies in JPH203-treated
tumors (p = 0.032) compared to vehicle-treated tumors
(Fig. 6e). We then evaluated the JPH203 treatment effi-
ciency in tumor cells in vivo. The transcription factor
ATF5 has been shown to be highly transcriptionally up-
regulated in vitro when cells are cultured in the absence
of leucine [35] and is widely accepted as indicator of the
amino acid stress response. Interestingly, Atf5 transcript
levels were significantly increased by 2.9-fold in JPH203
-treated tumors (Fig. 6f ). Finally we quantified the tran-
script levels of Slc7a8 encoding LAT2, which is func-
tionally equivalent to LAT1, and its heavy chain Slc3a2.
Importantly, both Slc7a8 and Slc3a2 transcripts were
not altered in JPH203-treated tumors (Fig. 6g).
LAT1 expression is significantly increased in human ATC
and associated with a shorter survival of patients
diagnosed with PTC
To address the importance of LAT1 in human thyroid
cancers, we obtained samples from patients, including
non-cancerous thyroids, PTC and ATC. SLC7A5 tran-
scription was significantly increased (4.9-fold) in the
ATC group compared to normal tissues (Fig. 6a, p =
0.03). Similar to the mouse model, SLC7A5 transcription
levels were intermediate in PTC samples (Fig. 7a).
To further investigate the potential role of LAT1 in
patients, the TCGA PTC dataset containing 400 tumor
samples with RNAseq and survival data was analyzed
[36] using the cBioPortal online platform [37, 38]. A
z-score threshold of 1 was used to define samples with
Fig. 5 The inhibition of LAT1 by JPH203 induces a cytostatic growth arrest in an ATC mouse model in vivo. a Outline of experimental procedure,
as described in the text. b Representative ultrasound images of vehicle- and JPH203-treated mice at day 0 and day 45. Images display the largest
thyroid cross-section, marked with the red line, at each time point. c Quantification of the weekly acquired US images of vehicle- (n = 4) and
JPH203-treated (n = 5) mice during the 45 days of treatment. Mice were treated for 5 consecutive days/week with either 50 mg/kg JPH203 or
vehicle (Captisol®) by i.p. injection. The largest thyroid cross-section was analyzed once per week and normalized to the largest thyroid cross-
section measured on day 0. Statistical analysis was performed using a two-way ANOVA test with Bonferroni correction for multiple comparisons.
d Body weight was measured every week and normalized to the initial weight at day 0
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increased SLC7A5 transcription. Survival analysis by
Kaplan-Meier estimate revealed that patients with high
SLC7A5 had a median survival of 98 months, whereas
the median survival of patients with lower SLC7A5 tran-
scription was undefined (Fig. 6b, p = 0.0113). Finally, we
addressed whether transcript levels of the sodium iodide
symporter (NIS, SLC5A5) were lower in the high
SLC7A5 group, because low SLC5A5 levels were
associated with radioiodine resistance [39]. Interestingly,
there was a significant co-occurrence of SLC5A5
Fig. 6 Tumors of JPH203-treated mice exhibit an increase in TUNEL-positive nuclei and activation of the amino acid stress response. H&E pictures
demonstrating PTC/ATC features in (a) a vehicle-treated mouse and PTC features in (b) a JPH203-treated mouse. c, d Ki67-positive cells and
BrdU-positive cells were quantified from each mouse and plotted in the graphs. e TUNEL-positive nuclei were quantified from each mouse and
plotted in the graph. f, g Atf5, Slc7a8 and Slc3a2 transcription levels were quantified in vehicle- and JPH203-treated animals. Transcription levels of
each gene were normalized to Tuba1a and plotted as fold change relative to vehicle level. All statistical analyses were performed by using a
two-tailed Mann-Whitney test
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downregulation with high SLC7A5 transcription (Fig. 7c,
p = 0.006). Furthermore we analysed two cohorts from
the GEO NCBI portal containing ATC samples com-
pared to non-tumoral tissues and/or PTC tissues. In
both cases ATC tissues presented significantly elevated
SLC7A5 transcription compared to normal tissues and
PTC (Additional file 1: Figure S2).
Discussion
The increased metabolism that is observed in tumors re-
quires elevated uptake of nutrients such as EAAs. The
EAA transporter LAT1 (SLC7A5) might play a crucial
role in this process, as it shows increased transcription
and/or expression in various tumors versus normal tis-
sues [40]. However, the evidence of a causal relationship
between LAT1 expression and tumor growth has been
addressed only in few reports [31, 41]. Additionally,
downregulation of SLC7A5 by shRNAs inhibited growth
of prostate [42] and gastric cancer cells [43], but did not
affect proliferation of cholangiocarcinoma cells [44] or
ovarian cancer cells [45]. Because of this apparent tissue
specificity of LAT1 in tumors, we became interested in
evaluating the role of this amino acid transporter in thy-
roid cancer in vitro and, more importantly, in vivo.
In experiments assessing the transcription levels of
SLC7A5 by TaqMan qPCR in different thyroid cancer
cell lines the prostate cancer cell line LNCaP was
used as a negative control [46] and the colon cancer
cell line HT-29, in which LAT1 is highly and func-
tionally expressed at the plasma membrane [31]
served as positive control. The expression of LAT1 in
all thyroid cancer cell lines was detectable at various
levels (Fig. 1a and b).
In order to use a suitable pharmacological tool we syn-
thesized the selective LAT1 inhibitor JPH203, which is
currently the only potent LAT1-specific inhibitor avail-
able. 3H-leucine uptake was reduced by 90% at concen-
trations of 1 μM JPH203 in the two ATC cell lines that
were analyzed, which demonstrated the dominant role of
LAT1-dependent leucine uptake in these cells (Fig. 1c).
Our control cell line HT-29 presented the expected potent
inhibition of leucine uptake by JPH203 that was similar to
the inhibition in 8505c and SW1736, while leucine uptake
was not affected by JPH203 in LNCaP cells lacking LAT1
expression (Additional file 1: Figure S1). Because the com-
pound did not induce efflux of 3H-leucine, which is typic-
ally observed by substrates like tyrosine or leucine [32],
but efficiently inhibited this process we conclude that
Fig. 7 LAT1 is upregulated in human ATC and associated with shorter survival in PTC patients. a SLC7A5 transcription levels were quantified in
normal thyroid (n = 10), PTC (n = 14) and ATC (n = 18) samples derived from patients. Transcription levels of each gene were normalized to ACTB
and plotted as fold change relative to normal thyroid. Statistical analysis was performed using a Kruskal-Wallis test with Dunn’s correction for
multiple comparisons, p-value is indicated. b The PTC dataset (TCGA, Cell 2014) containing 400 tumor samples with RNAseq and survival data was
analyzed using the cBioPortal online platform. Z-score > 1 was used to define samples with high SLC7A5 expression (n = 36) and z-score < 1 was
used to define samples with low SLC7A5 expression (n = 364). Statistical analysis was performed by using a log-rank test, p-value is indicated.
c SLC5A5 expression levels were analyzed in the PTC dataset from (b) and co-occurrence of SLC5A5 downregulation (defined as expression
< median) with high SLC7A5 (z-score > 1) was quantified. Statistical analysis was performed by using a one-sided Fisher’s exact test
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JPH203 is a non-substrate inhibitor that likely is competi-
tive. This is also supported by the fact that proliferation
inhibition by JPH203 was only observed when the EAA
concentration was reduced (Figs. 2e). This is consistent
with the recently published report showing that in a
leukemia model, the JPH203 anti-proliferative effect is re-
duced by addition of EAA but not by NEAA [41].
We cannot exclude minor LAT1 independent leucine
uptake, as seen in LAT1 deleted LS174T cells that con-
tinue to grow in DMEM medium [47], but at low EAA
concentrations the ATC cell lines were almost solely de-
pending on LAT1 for their leucine uptake.
Blocking LAT1 by JPH203 reduced proliferation of 5
out of 6 thyroid cancer cells with relative IG50 ranging
from 1.3 μM to 6.8 μM. The PTC cell line K1 was less
sensitive (16.9 μM), reflecting the reduced LAT1 expres-
sion in this line. In agreement with these findings,
JPH203 at concentrations below 15 μM did not display
any anti-proliferative effect on LNCaP cells with a rela-
tive IG50 calculated above 100 μM, while for HT-29 cells
an IG50 of 4.1 μM was reported [31]. Thus, only at full
blockage of leucine uptake an anti-proliferative effect
was seen. Although we cannot exclude any unspecific ef-
fects of JPH203 in ATC cell lines, the fact that JPH203
did not affect proliferation of LNCaP cells below 10 μM
indicates that off-target effects are unlikely at this
concentration.
Nicklin et al. have well studied the relationship be-
tween LAT1-dependent leucine uptake and mTOR [3].
Here, we used Phospho-S6 and Phospho-p70S6K as
readouts for mTORC1 activity and found a decrease of
Phospho-S6 and Phospho-p70S6K levels in all JPH203
-treated thyroid cancer cells which indicates that
mTORC1 activity is affected (Fig. 3). Interestingly we
found that the ERK pathways was not negatively affected
by the drug, and neither was AKT phosphorylation. This
demonstrates the specificity of the drug and that the ef-
fect observed is not a general deterioration of the condi-
tion of the cells. mTORC1 alteration is consistent with a
previous report, which showed that LAT1 inhibition by
JPH203 reduced mTORC1 activity in T-cell lymphoma
cells [41]. Apart from leukemia cells, blocking all LATs
(LAT1–4) by BCH reduced mTORC1 activity in HeLa
cells [3]. However, to our knowledge, this is the first re-
port indicating that the specific inhibition of LAT1 by
JPH203 affects mTORC1 in carcinoma cells. This sug-
gests that LAT1 could be used to modulate mTORC1 in
a tumor-specific manner, potentially avoiding the side ef-
fects of systemic mTOR inhibition.
Noteworthy, at low levels of EAA (0.25× or 0.125×)
the leucine concentration is closer to the physiological
levels observed in plasma (Additional file 1: Table S1
and supplementary material of [33]. In order to translate
the above observations to an in vivo situation we took
advantage of a genetically engineered mouse model of
thyroid cancer. In this model, which thyroid-specifically
express BRAFV600E and PIK3CAH1047R mutations leading
to constitutively active MAPK and Pi3’K pathways, it
was previously demonstrated that 3–6 months after tam-
oxifen induction the tumors display both PTC and ATC
features [27]. Based on this, we selected the four-months
time point to start the JPH203 treatment to subse-
quently asses its effect on thyroid growth in late-stage
disease. Slc7a5 transcription was increasing with tumor
progression from wild-type to BRAFV600E single-mutant
tumors, which correspond to benign and PTC lesions,
and BRAFV600E/PIK3CAH1047R double-mutant tumors
that consisted of PTC and ATC foci (Fig. 4a). Concomi-
tantly, the transcription level of SLC7A5 was lower in
the PTC cell line K1 when compared to the ATC cell
lines 8505c and SW1736 (Fig. 1a). This is consistent with
the fact that LAT1 is associated with invasive behavior
of cancer cells [48, 49] and that ATC is a very invasive
highly aggressive tumor subtype in which most patients
are not suitable for surgery anymore due to local inva-
sion at initial diagnosis [19]. Similarly to studies indicat-
ing that 4F2hc (SLC3A2) is overexpressed during the
progression of breast and pancreatic cancer [8, 11], we
detected significantly increased transcript levels of
Slc3a2 in BRAFV600E/PIK3CAH1047R double-mutant tu-
mors (Fig. 4a). Our data indicate that 4F2hc expression
increased in parallel with LAT1 in order to enhance
LAT1 activity in thyroid cancer. Finally, we found that
ASCT2 (Slc1a5), which works together with LAT1, was
not altered in BRAFV600E single-mutant tumors or
BRAFV600E/PIK3CAH1047R double-mutant tumors. How-
ever, in the BRAFV600E/PIK3CAH1047R double-mutant
tumors the functionally equivalent transporter Slc38a2
(SNAT2) was 2.2-fold increased, although not statisti-
cally significant it could still partially compensate the
lack of increased Slc1a5 transcription (Fig. 4a). Thus, in
this mouse model all the partners required for
LAT1-dependent leucine uptake were transcribed and in
some cases upregulated with tumor progression. Since
c-MYC has been shown in the context of pancreatic can-
cer cells to drive SLC7A5 transcription [34], in our
mouse model we have tested the relative role of the
RAF-MEK-ERK and Pi3’K pathways for Slc7a5 transcrip-
tion. MEK inhibition was very potent in reducing Slc7a5
transcripts while Pi3’K inhibition was not (Fig. 4b). This
reflects the apparent predominant role of BRAFV600E to
induce LAT1 elevation. It was also worth noticing that
while LNCaP cells were affected by EAA reduction,
8505c expressing LAT1 cells showed a resistance to this
“amino acids starvation” (Fig. 2a and d). Importantly,
JPH203 exposure restored “amino acids starvation” sen-
sitivity in 8505c similarly to LNCaP cells. Furthermore
amino acids concentration in blood and therefore in
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tissues are at similar levels as in our “amino acids starva-
tion” condition (Additional file 1: Table S1). Taken to-
gether these date suggest that BRAFV600E induces LAT1
elevations that confers tumor cells the ability to grow in
the nutrient-limited environment.
To study the effect of LAT1 inhibition in thyroid can-
cer in vivo, mice were treated with a previously estab-
lished effective dose of JPH203 at 50 mg/kg [41]. Oda et
al. demonstrated that applying a dose of 25 mg/kg
JPH203 in mice results in a plasma concentration of
2.4 μM that is maintained during at least 4 h [31].
Therefore, we assumed that the 50 mg/kg dose could re-
sult in a plasma concentration, sufficient to block LAT1
according to our in vitro data (Fig. 1 and 2). Interest-
ingly, treated-mice presented a cytostatic effect with a
tumor growth arrest after 14 days of treatment and sub-
sequent stable disease (Fig. 5c). Proliferation markers
(Ki67, BrdU) were not significantly decreased in
JPH203-treated tumors (Fig. 6c and d) while apoptosis
was elevated as demonstrated by TUNEL staining (Fig.
6e). This observation is compatible with mTOR inhib-
ition that is often associated with increased apoptosis.
The increase of apoptosis associated with no measurable
modifications of tumor proliferation resulted in an ap-
parent tumor size stabilization or “zero net gain”. Im-
portantly, the strong 2.9-fold increase of Atf5
transcription in JPH203-treated tumors suggests that
LAT1 inhibition depleted EAA concentration in tumor
cells in vivo (Fig. 6f ). The fact that Slc7a8, which is func-
tionally equivalent to LAT1, was not transcriptionally
upregulated in JPH203-treated tumors indicates that this
transporter was not able to compensate for the lower
LAT1 activity (Fig. 6g). For the most aggressive cases
with a survival median of 5 months such effect would
most likely translate into clinical benefit.
The increased Slc7a5 transcription found in the mouse
model (Fig. 4a) is consistent with the findings in human
ATC (Fig. 7a) underscoring that LAT1 could also be in-
volved in human ATC tumors. In addition, in the dataset
available at TCGA Data Portal, focusing on PTC [36]
showed a significant difference in the 5-year survival be-
tween patients with high and low SLC7A5 levels. The es-
timated long-term survival was significantly reduced for
patients with high SLC7A5 transcript levels (Fig. 7b)
even if the disease progression free analysis did not show
any difference (data not shown). While these data have
to be taken carefully, further analyses from GEO data-
sets [50, 51] showed SLC7A5 increase from normal tis-
sue to PTC and ATC (Additional file 1: Figure. S2)
emphasizing the fact that SLC7A5 is associated with the
most aggressive untreatable cases of thyroid cancers. Fi-
nally, the finding of high SLC7A5 levels significantly
co-occurring with low SLC5A5 transcripts (Fig. 7c)
might indicate that LAT1 is associated with aggressive
forms of thyroid cancer like RAI refractory PTC. This is
in line with reports on prostate cancer, pancreatic cancer
and neuroendocrine lung tumors, in which high LAT1
expression was correlated with poor survival [7, 10, 11].
Conclusions
Our data show that LAT1 plays a critical role in tumor
growth in mice and mTORC1 activity in human thyroid
cancer cell lines, suggesting that LAT1 helps cells grow
in the physiological environment that is low in amino
acids. Additionally, using a genetically engineered mouse
model that recapitulates the development of human
ATC, we observed significant growth arrest when LAT1
was inhibited by the non-substrate LAT1 inhibitor
JPH203. This is the first study to show the preclinical
benefit of blocking LAT1 for solid tumor in immuno-
competent mice. Finally, in human thyroid cancer pa-
tients, LAT1 expression levels seem to correlate with
tumor progression, poorer outcome and radioiodine re-
sistance. Therefore, LAT1 should be considered as a po-
tential therapeutic target in the development of new
anticancer drugs in the context of unresectable and non
iodine-treatable thyroid cancers.
Additional file
Additional file 1: Figure S1. Leucine uptake in negative control cells
LNCaP. Figure S2. LAT1 transcription levels in GSE datasets 65144 and
33630. Table S1. Comparison of the amino acid concentrations (in μM)
in different media versus plasma. (PDF 104 kb)
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